

MOL #35170

Title Page

Title: “A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis”

Michael A. Benneyworth
Zixiu Xiang*
Randy L. Smith
Efrain E. Garcia
P. Jeffrey Conn
Elaine Sanders-Bush

Affiliation:
Department of Pharmacology,
Vanderbilt University School of Medicine
Nashville, TN
(M.A.B., Z.X., R.L.S., E.E.G., P.J.C, E.S-B)

*co-first author

MOL #35170

Running Title Page

Running Title: “Selective mGluR2 activation blocks effects of a hallucinogen”

Corresponding Author:

Elaine Sanders-Bush

Department of Pharmacology,

Vanderbilt University School of Medicine

8140 MRB III

Nashville, TN, 37232

Email: Elaine.bush@vanderbilt.edu

Tel.: (615) 936-1685

Fax: (615) 322-4421

Number of Text Pages: 32

Number of Figures: 4

Number of Tables: 1

Number of References: 40

Number of words in Abstract: 245

Number of words in Introduction: 585

Number of words in Discussion: 1218

Non-standard abbreviations: mGlu, metabotropic glutamate; mPFC, medial prefrontal cortex; BINA, biphenyl-indanone A; 5-HT_{2A}, serotonin subtype 2A; EPSC, excitatory postsynaptic current; SSC, somatosensory cortex; Fos-LI, Fos-like immunoreactive; PBS, phosphate-buffered saline; ACSF, artificial cerebrospinal fluid

MOL #35170

Abstract

Recent clinical studies reveal that selective agonists of group II metabotropic glutamate (mGlu) receptors have robust efficacy in treating positive and negative symptoms in schizophrenia patients. Group II mGlu receptor agonists also modulate the *in vivo* activity of psychotomimetic drugs, and reduce the ability of psychotomimetic hallucinogens to increase glutamatergic transmission. Because increased excitation of the medial prefrontal cortex (mPFC) has been implicated in pathophysiology of schizophrenia, the ability of group II mGlu receptor agonists to reduce hallucinogenic drug action in this region is thought to be directly related to their antipsychotic efficacy. Recently, a novel class of ligands, termed positive allosteric modulators, has been identified, displaying exceptional mGlu2 receptor selectivity. These compounds do not activate mGlu2 receptors directly but potentiate the ability of glutamate and other agonists to activate this receptor. We now report that the mGlu2 receptor-selective positive allosteric modulator, biphenyl-indanone A (BINA), modulates excitatory neurotransmission in the mPFC and attenuates the *in vivo* actions of the hallucinogenic 5-HT_{2A/2C} receptor agonist, (-) 2,5-dimethoxy-4-bromoamphetamine (DOB). BINA attenuates serotonin-induced increases in spontaneous excitatory postsynaptic currents in the mPFC, mimicking the effect of the mGlu2/3 receptor agonist DCG-IV. In addition, BINA reduced (-)DOB-induced head twitch behavior and Fos expression in mPFC, effects reversed by pretreatment with the mGlu2/3 receptor antagonist LY341495. These data confirm the relevance of excitatory signaling in the mPFC to the behavioral actions of hallucinogens and further support the targeting of mGlu2 receptors as a novel strategy for treating glutamatergic dysfunction in schizophrenia.

MOL #35170

Introduction

Psychotomimetic drugs, including dissociative anesthetics (phencyclidine and ketamine) and hallucinogens (lysergic acid diethylamide and psilocybin), are commonly used in experimental models of psychosis to probe the pathophysiology of schizophrenia. In humans, these drugs produce a state of drug intoxication that resembles many of the symptoms of acute schizophrenia (Vollenweider and Geyer, 2001). Additionally, human brain imaging demonstrates a common pattern of increased activity in the frontal cortex caused by psychotomimetic drugs and acute schizophrenia (Cleghorn et al., 1989; Hermle et al., 1993; Kaplan et al., 1993; Ebmeier et al., 1995; Vollenweider et al., 1997a; Vollenweider et al., 1997b), suggesting a potential role of the excitatory neurotransmitter glutamate in psychotic behaviors. The release of glutamate from nerve terminals is negatively regulated by group II mGlu receptors, mGlu2 and mGlu3 subtypes. Recent evidence that the behavioral effects of ketamine in humans are disrupted by an mGlu2/3 receptor agonist (Krystal et al., 2004) supports the targeting mGlu2/3 receptors as a therapeutic target for schizophrenia. Consistent with this hypothesis, data from a recent phase II clinical trial shows that an mGlu2/3 receptor agonist is an effective antipsychotic therapy, comparable to the atypical antipsychotic drug, olanzapine (Schoepp, 2006). These studies demonstrate the therapeutic potential of mGlu2/3 receptors and indicate the need to further investigate the individual roles of mGlu2 and mGlu3 receptors in behavior and glutamatergic neurotransmission.

Investigation of hallucinogenic drug action as a model of psychosis suggests that the behavioral effects of hallucinogens in humans are mediated by activation of serotonin (5-HT) subtype 2A (5-HT_{2A}) receptors (Vollenweider et al., 1998). Hallucinogen-

MOL #35170

induced activation of 5-HT_{2A} receptors increases spontaneous excitatory postsynaptic currents (EPSCs) in layer V pyramidal neurons of the mPFC (Aghajanian and Marek, 1997, 1999), consistent with the induction of glutamate release from presynaptic nerve terminals. Extensive electrophysiological experiments demonstrate a physiological antagonism between 5-HT_{2A} receptors and mGlu2/3 receptors in mPFC (Marek et al., 2000), with activation of mGlu2/3 receptors dramatically attenuating 5-HT_{2A} receptor-induced EPSCs, supporting the use of hallucinogens as a model for studying the regulation of hyperactive glutamatergic signaling by mGlu2/3 receptors *in vivo*. Consistent with this model, mGlu2/3 receptor agonists attenuate behavioral effects of hallucinogens (Gewirtz and Marek, 2000; Klodzinska et al., 2002; Winter et al., 2004), as well as, dissociative anesthetics (Moghaddam and Adams, 1998; Cartmell et al., 1999; Greco et al., 2005; Galici et al., 2005).

Although preclinical and clinical studies clearly illustrate that group II mGlu receptors are viable antipsychotic targets, conclusions are hindered by the lack of selectivity of all available pharmacological tools for the individual group II mGlu receptor subtypes. Recently, a novel class of mGlu2 receptor-selective ligands, known as positive allosteric modulators, has been developed and shown to have *in vivo* properties in behavioral assays of antipsychotic and anxiolytic activity that mimic mGlu2/3 receptor agonists (Johnson et al., 2003; Galici et al., 2005; Johnson et al., 2005; Galici et al., 2006). Positive allosteric modulators do not activate the receptor directly but act at a site separate from the glutamate binding site to potentiate the agonist response, inducing a leftward shift in the glutamate concentration-response curve (Schaffhauser et al., 2003; Johnson et al., 2003; Johnson et al., 2005; Galici et al., 2006). Biphenyl-indanone A

MOL #35170

(BINA), a recently characterized, positive allosteric modulator of mGlu2 receptors with *in vivo* activity, is highly selective for mGlu2 receptor over other mGlu receptor subtypes (Galici et al., 2006). The current study takes advantage of BINA to test the ability of selective potentiation of mGlu2 receptors to attenuate the actions of the hallucinogenic 5-HT_{2A} receptor agonist (-)2,5-dimethoxy-4-bromoamphetamine (DOB).

MOL #35170

Materials and Methods

Brain Slice Electrophysiology.

Brain slices were prepared from Sprague Dawley rats (postnatal day 16-24). Rats were anesthetized with isoflurane. The brain was rapidly removed and submerged in ice-cold modified oxygenated artificial cerebrospinal fluid (ACSF), composed of 230 mM sucrose, 2.5 mM KCl, 0.5 mM CaCl₂, 10 mM MgSO₄, 1.25 mM NaH₂PO₄, 26 mM NaHCO₃, and 10 mM D-glucose. Coronal brain slices (300 μm) containing the mPFC were cut using a Leica VT1000S vibratome (Leica Microsystems, Nussloch, Germany). Slices were incubated in oxygenated ACSF at 32°C for 1 hour and maintained at room temperature until transferred to a recording chamber. The recording chamber was continuously perfused at ~30°C with oxygenated ACSF, containing 126 mM NaCl, 2.5 mM KCl, 3.0 mM CaCl₂, 2.0 mM MgSO₄, 1.25 mM NaH₂PO₄, 26 mM NaHCO₃, and 10 mM D-glucose.

Spontaneous excitatory postsynaptic currents (EPSCs) were recorded from layer V pyramidal cells in whole-cell voltage-clamp mode using an Axon Multiclamp 700B amplifier (Molecular Devices, Union City, CA) and visualized with an Olympus BX50WI upright microscope (Olympus, Lake Success, NY) coupled with a 40x water immersion objective and Hoffman optics. Borosilicate glass (WPI, Sarasoto, FL) patch pipettes were prepared using a Flaming-Brown micropipette puller (Model P-97, Sutter Instruments, Novato, CA) and filled with 123 mM K-gluconate, 7 mM KCl, 1 mM MgCl₂, 0.025 mM CaCl₂, 10 mM HEPES, 0.1 mM EGTA, 2 mM ATP and 0.2 mM GTP at a pH of 7.3 and osmolarity of ~ 295 mOsm. Filled patch pipettes had resistances of 2-

MOL #35170

3 M Ω . EPSCs were recorded at a holding potential of -70 mV; GABA_A receptor-mediated inhibitory currents were undetectable under these conditions. The voltage-clamp signal was low-pass filtered at 2 kHz, digitized at 10 kHz and acquired using a Clampex9.2/DigiData1332 system (Molecular Devices, Union City, CA). All drugs were bath-applied. After a stable baseline was recorded for 5-10 minutes, the effect of BINA or DCG-IV on baseline EPSCs or 5-HT-induced EPSCs (applied 3 minutes after 5-HT) were examined.

***In vivo* Studies**

Subjects. (-)DOB-induced head twitch response and Fos expression were examined in male ICR(CD-1) mice (Harlan, Indianapolis, IN) at 8-10 weeks of age. Mice were housed in groups of four or five animals per cage in a large colony room on a 12:12 light/dark cycle with light onset at 6:00 am. Food and water were provided *ad libitum*. All experiments were performed in compliance with the guide for the Principles of Laboratory Animal Care (NIH publication No. 85-23, revised 1996).

Head twitch response. Mice were transferred from the colony room to the observation room and allowed to habituate for 30 minutes. All experiments used a between-subject design. Mice (n=6) were treated one at a time in random order with LY341495 (3.0 mg/kg, i.p.) or saline (i.p.), followed 10 minutes later with either BINA (65 mg/kg, i.p.) or vehicle, and 30 minutes later with (-)DOB (0.3 mg/kg, s.c.). Immediately following injection of (-)DOB, mice were placed in a 3L glass beaker and observed for 30 minutes by two observers, one of whom was blind to the treatment. Head twitch responses were recorded in 5-min time bins. Counts from the two observers were averaged, with data

MOL #35170

shown to be consistent between the two. Three or four mice were evaluated per day, between 1:00 and 4:00 pm, and treatments were randomized across the test days.

Fos expression experiments. Mice were handled daily for 2 weeks prior to drug treatment. On the day of treatment, mice were moved from the colony room into an isolation room and allowed to habituate for 30 minutes. Mice (n=7) were given either LY341495 (3.0 mg/kg, i.p.) or saline, followed 10 minutes later by BINA (65 mg/kg, i.p.) or vehicle and 30 minutes later with (-)DOB (1.0 mg/kg, s.c.) or saline (s.c.).

Experiments were performed between 10:30 am and 4:30 pm over three consecutive days with 12-20 animals evaluated per day. Treatments were randomized throughout the three days.

The immunohistochemical procedure was modified from a previously published study performed in rats (Gresch et al., 2002). Mice were deeply anesthetized with pentobarbital (250 mg/kg) and transcardially perfused with 0.1 M phosphate-buffered saline (PBS) then with 0.1 M PBS containing 4% paraformaldehyde. Brains were post-fixed overnight in paraformaldehyde and stored in a solution of 30% sucrose until sectioned. Coronal sections (40 μ m) were made using a sliding microtome and placed in cryoprotectant solution (30 % glycerol, 30% ethylene glycol, 30% Milli-Q water, 10% 0.2 M phosphate buffer). Immunohistochemistry was performed on free floating sections. Slices were treated with 0.3% hydrogen peroxide for 20 minutes, and blocking solution (5% normal goat serum, 2% Triton X-100) for 1 hour, Fos primary antibody (Ab-5, polyclonal antisera; Calbiochem, La Jolla, CA) diluted 1:20,000 in blocking solution for 48 hours at 4°C, secondary antibody (biotinylated anti-rabbit IgG; Vector laboratories, Burlingame, CA), diluted 1:1000 in blocking solution for 90 minutes, and

MOL #35170

finally ABC solution (Vector laboratories) for 60 minutes. For colorimetric detection of Fos-like immunoreactivity (Fos-LI), washed sections were treated for 7 minutes with 3,3'-diaminobenzidine (DAB) in 0.001% hydrogen peroxide.

Fos-LI positive cells were counted in brain sections containing mPFC and SSC (Franklin and Paxinos, 2003). For each subject, two slices were analyzed bilaterally, resulting in four replicate determinations. Bright-field video images were captured using Openlab 2.2.5 software (Improvision, Lexington, MA) with a Coolsnap cf (Photometrics, Tuscon, AZ) video camera system mounted on a Zeiss Axiovert S100 microscope at 10x magnification. The number of Fos-LI positive cells in a 600 μ m \times 450 μ m area was counted using ImageJ 1.33u (Wayne Rasband, NIH) software. Two program parameters, pixel density and size, were used to define the threshold for a positive count. The four replicate determinants were averaged for each subject.

Drugs

BINA was synthesized by the Vanderbilt Institute for Biological Chemistry Core, as previously described (Galici et al. 2006). For *in vitro* experiments, BINA was dissolved in DMSO then diluted to the appropriate concentration. For *in vivo* experiments, BINA was dissolved in 10% Tween 80 and 10 % 1N NaOH and the pH was adjusted to 7.4 using 8.5% lactic acid. (-)DOB was provided by the National Institute of Drug Abuse. LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionic acid] and DCG-IV [(2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine] (Tocris Bioscience, Ellisville, MO) were dissolved in deionized water. M100907 [R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methanol], a gift

MOL #35170

from Merrill Dow (Cincinnati, OH), was dissolved in a minimal volume of 2% tartaric acid and brought up to volume in deionized water. LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate], a gift from Eli Lilly and Co. (Indianapolis, IN), was dissolved in deionized water.

Statistical Analyses

In electrophysiological experiments, EPSCs were detected and analyzed using Mini Analysis Program (Synaptosoft, Decatur, GA, USA). The peak amplitude and inter-event interval (IEI) of EPSCs from 30 second episodes during control and drug application were used to generate cumulative probability plots and the statistical significance was determined by Kolmogorov-Smirnov test (K-S test). The mean values of EPSC amplitude and IEI from the 30 second episode were grouped (mean \pm SEM) and compared using a paired two-tail t-test; p-value <0.05 was considered statistically significant.

For head twitch and Fos expression studies, data were compiled and analyzed using one-way ANOVA, with Newman-Keuls post hoc tests (GraphPad Prism 4.00). Statistical difference was defined as a p-value <0.05 . Head twitch and Fos expression data are expressed as mean \pm SEM.

MOL #35170

Results

BINA acts synergistically with mGlu2/3 receptor agonist to block baseline

spontaneous EPSCs. Consistent with previous studies, 1 μ M DCG-IV, mGlu2/3 receptor agonist, reduces the frequency of spontaneous EPSCs in layer V pyramidal neurons in the mPFC (Fig. 1A-D), while 200 nM DCG-IV was ineffective (Fig. 1E-H). Furthermore, a concentration of BINA (3 μ M) that maximally potentiates mGlu2 receptor-mediated responses in cell lines (Galici et al., 2006) had no effect on spontaneous EPSCs (Fig. 1I-L). However, addition of 200 nM DCG-IV, in the presence of 3 μ M BINA, reduced both the frequency and amplitude of the EPSCs to 49.7 ± 6.3 % and 80.6 ± 7.0 % of control values, respectively (Fig. 1I-L). This synergistic interaction of BINA and DCG-IV on baseline EPSCs demonstrates that BINA acts as an allosteric potentiator of the mGlu2 receptor.

BINA attenuates 5-HT-induced EPSCs, mimicking mGlu2/3 receptor agonist, and is

blocked by an mGlu2/3 receptor antagonist. Application of 5-HT (10 μ M) induced a robust increase in the frequency and amplitude of spontaneous EPSCs, which was maximal at 2 minutes and diminished after 9 minutes of persistent activation with frequency and amplitude equal to 73.1 ± 4.2 % and 88.6 ± 4.3 % of the stimulation measured at 2 minutes (data not shown). The 9 minute time point is used for further drug treatment comparison, with data normalized to the maximal stimulation observed at 2 minutes. The 5-HT-induced EPSCs were blocked by the 5-HT_{2A} receptor antagonist, M100907 (100 nM), and the AMPA receptor antagonist, CNQX (20 μ M) (data not

MOL #35170

shown), consistent with the interpretation that 5-HT_{2A} receptor activation modulates excitatory signaling via release of glutamate.

The 5-HT-induced increase in spontaneous EPSCs is regulated by mGlu2/3 receptors, acting as presynaptic autoreceptors on thalamocortical glutamatergic terminals within the mPFC (Marek et al., 2000). Although not directly addressed, the current data is consistent with the interpretation that a similar mechanism explains the action of the mGlu2/3 receptor agonists in our preparation. Comparison of 5-HT-induced EPSCs in the presence of BINA (3 μ M) and DCG-IV (100 nM) demonstrates the ability of selective mGlu2 receptor manipulation to reduce 5-HT-induced EPSCs in a manner similar to the mGlu2/3 receptor agonist (Fig. 2A-F). Both frequency (Fig. 2J) and amplitude (Fig. 2K) of 5-HT-induced EPSCs are decreased in the presence of BINA or DCG-IV. BINA significantly reduced the frequency ($52.2 \pm 5.2\%$ of maximum stimulation) and amplitude ($72.7 \pm 3.7\%$ of maximum stimulation) of EPSCs, mimicking the effect of DCG-IV ($39.6 \pm 7.2\%$ and $64.3 \pm 3.7\%$). These values were all significantly lower than those for 5-HT alone. Figure 2G-I illustrates that, in the presence of mGlu2/3 receptor antagonist LY341495 (100nM), BINA (3 μ M) failed to reduce the frequency (Fig.2J) and amplitude (Fig. 2K) of 5-HT-induced EPSCs. These parameters measured in the presence of BINA and LY341495 are similar to values for 5-HT alone.

BINA-mediated blockade of (-)DOB-induced head twitch response is reversed by mGlu2/3 receptor antagonist. Hallucinogenic drugs have been repeatedly shown to induce a stereotyped head twitch in rats and mice that is linked to activation of 5-HT_{2A} receptors (Schreiber et al., 1995; Willins and Meltzer, 1997; Gewirtz and Marek, 2000;

MOL #35170

Klodzinska et al., 2002). This stereotyped behavior is robust and distinct from other stereotyped movements, such as rearing, ear scratching, and sniffing. The head twitch response was assessed in male ICR(CD-1) mice; it became apparent within 5 minutes of subcutaneous injection of (-) DOB (0.3 mg/kg), and peaked approximately 20 minutes following treatment (data not shown). In agreement with previous studies (Klodzinska et al., 2002), pretreatment with the mGlu2/3 receptor agonist LY379268 (3.0 mg/kg, i.p.) significantly reduced the (-)DOB-induced head twitches (data not shown). The ability of BINA (65 mg/kg) to mimic the action of the mGlu2/3 receptor agonist was examined in the presence or absence of the mGlu2/3 receptor antagonist LY341495 to further test the *in vivo* selectivity of BINA (Fig. 3). One-way ANOVA revealed a significant effect of pretreatment on the (-)DOB-induced head twitch response [$F(3,20)=15.08$, $p<0.001$]. Post hoc analysis demonstrates that BINA was able to significantly attenuate the (-)DOB-induced head twitch response (6.3 ± 1.2 vs. 24.3 ± 2.3). Pretreatment with LY341495 (3.0 mg/kg, i.p.) had no effect alone, but significantly reversed of the effects of BINA on the (-)DOB-induced head twitch response (19.8 ± 2.0 vs. 6.3 ± 1.2).

The *in vitro* pharmacological profile of BINA for mGlu receptors was extensively evaluated by Galici et al. (2006), showing in cell expression systems that BINA possessed selective activity at mGlu2 receptor to the exclusion of any effect on glutamate-induced signaling at mGlu1, mGlu3, mGlu4 or mGlu5 receptors. While indicating selectivity of BINA for various mGlu receptor subtypes, the possibility remained that this novel compound interacts with 5-HT_{2A} receptors, which would compromise interpretation of its effects *in vivo*. In control studies, we found that BINA did not alter the binding of the 5-HT_{2A} receptor antagonist, [³H]-ketanserin, or (-)DOB-

MOL #35170

induced phosphoinositide hydrolysis in cells expressing the 5-HT_{2A} receptor (data not shown), ruling out the possibility that the observed effects of BINA involve direct binding to or allosteric modulation of the 5-HT_{2A} receptor.

BINA suppresses (-)DOB-induced Fos expression in medial prefrontal cortex, but not somatosensory cortex. The rapid, transient expression of the immediate early gene, *cfos*, occurs following neuronal activation, thus providing an *in vivo* map of the cellular response to an excitatory stimulus (Chaudhuri 1997). The protein product of the *cfos* gene, Fos, was examined in the mPFC and SSC (Figure 4). A preliminary dose-response experiment showed that a dose of 1.0 mg/kg (-)DOB resulted in a significant, but submaximal Fos signal (data not shown). Pretreatment with M100907 (0.5 mg/kg), a 5-HT_{2A} receptor antagonist, prevented (-)DOB-induced Fos expression in both mPFC and SCC (data not shown). The effects of BINA on the (-)DOB Fos signal in mPFC are summarized in Table 1. One-way ANOVA indicated a significant effect of treatment condition [F(6,42)=7.12, p<0.001]; post hoc analysis demonstrated that (-)DOB significantly increased the number of Fos-LI positive cells compared to the baseline, saline treatment. Additionally, BINA (65 mg/kg) completely prevented the (-)DOB-induced Fos expression with no effect on baseline Fos expression. Finally, pretreatment with LY341495 (3.0 mg/kg) was able to antagonize the actions of BINA, with no significant potentiation of (-)DOB alone. LY341495 induced a significant increase in baseline Fos-LI positive cells.

Previous work demonstrated that the hallucinogen-induced *cfos* expression was regulated by mGlu2/3 receptors in the mPFC, but not in the somatosensory cortex (SSC)

MOL #35170

(Zhai et al., 2003). To determine if this regional specificity also applies to an mGlu2 selective agent, we extended the Fos analyses to the SSC (Table 1), where a significant effect of treatment condition was found [one-way ANOVA, $F(6,42)=7.12$, $p<0.001$]. (-)DOB induced a significant increase in Fos-LI positive cells, with a distribution of Fos-LI positive cells throughout a “band” from deep layer III through superficial layer V. However, the (-)DOB-induced expression in the SSC was not significantly altered by either BINA or LY341495, demonstrating specificity of this neuronal response.

MOL #35170

Discussion

As mGlu2/3 receptor agonists continue to gain notoriety for their antipsychotic actions in humans, reducing symptoms of schizophrenia and the effects of the psychotomimetic ketamine (Krystal et al., 2004; Schoepp 2006), it is becoming increasingly important to further delineate the individual roles of mGlu2 and mGlu3 receptors. The recent development of BINA, a selective mGlu2 receptor allosteric potentiator, makes possible the pharmacological evaluation of mGlu2 receptors, in the absence of any potential confounding activation of mGlu3 receptors. In *in vitro* electrophysiological and *in vivo* behavioral and gene expression studies, we show that selective activation of mGlu2 receptors mimics a non-selective mGlu2/3 receptor agonist, attenuating the actions of hallucinogenic drugs and glutamatergic neurotransmission in the mPFC.

Using whole-cell recordings in brain slices, we evaluated the consequences of selective modulation of mGlu2 receptors with the positive allosteric modulator, BINA. BINA, at a concentration that had no effect alone, potentiates the actions of a subeffective concentration of DCG-IV to block baseline EPSCs, confirming that BINA acts as an allosteric potentiator of the mGlu2 receptor. At a concentration that had no effect on baseline EPSCs, BINA attenuates 5-HT-induced EPSCs, mimicking the mGlu2/3 receptor agonist, DCG-IV. Importantly, BINA is capable of reducing 5-HT-induced EPSCs when added alone, in the absence of exogenous agonist. This is the first example of an electrophysiological response to an allosteric potentiator of an mGlu receptor that does not require concomitant application of an agonist. Since BINA is not capable of directly activating mGlu2 receptors in the absence of an orthosteric agonist (Galici et al.,

MOL #35170

2006), this suggests that BINA potentiates low levels of endogenous glutamate that have access to presynaptic mGlu2 receptors and that selective activation of mGlu2 receptors is an exquisitely sensitive mechanism for regulation of hyperglutamatergic transmission.

Hallucinogenic drugs have previously been shown to induce glutamatergic signaling in the mPFC, a brain region thought to underlie their behavioral effects and some of the psychological symptoms of schizophrenia. The hallucinogenic 5-HT_{2A} receptor agonist (-)DOB is used here to investigate the role that selective activation of mGlu2 receptors plays in the regulation of glutamatergic neurotransmission. Past studies have provided a hypothetical model of *in vivo* hallucinogenic drug action (Aghajanian and Marek, 2000) in which agonism at 5-HT_{2A} receptors results in activation of glutamatergic neurotransmission in the mPFC linked to a presynaptic modulation of glutamate release from thalamocortical afferent neuronal terminals (Aghajanian and Marek 1997, 1999; Marek et al., 2000; Marek et al., 2001). Selective expression of mGlu2 receptor mRNA in midline and intralaminar thalamic nuclei (Ohishi et al., 1993a), the region containing neurons known to project to the mPFC, suggests a dominant role of mGlu2 receptor in the presynaptic action of mGlu2/3 receptor ligands at thalamocortical terminals. Our experiments showing that BINA, a selective mGlu2 receptor positive allosteric modulator, attenuates 5-HT-induced EPSCs in the mPFC are consistent with this hypothesis.

A major finding of the current study is the ability of BINA to block the (-)DOB-induced head twitch response, mimicking the actions of a mGlu2/3 receptor agonist, demonstrating that the regulation of hallucinogen-induced behavior is reproduced by the selective activation of mGlu2 receptors. Blockade of head twitch response was observed

MOL #35170

in a dose range that is similar to the previously reported BINA attenuation of the behavioral effects of the non-competitive NMDA receptor antagonist, phencyclidine (Galici et al., 2006). This result suggests that the dampening effects of mGlu2/3 receptor agonists on psychotomimetic drug-induced behaviors (Gewirtz and Marek 2000; Klodzinska et al., 2002; Winter et al., 2004) are likely due to the activation of mGlu2 receptor. Furthermore, *in vivo* selectivity of BINA was confirmed by a reversal of the blockade of head twitch response by pretreatment with the mGlu2/3 receptor antagonist, LY341495. These data strongly support a reciprocal relationship between mGlu2 and 5-HT_{2A} receptors in the behavioral actions of hallucinogens, and illustrate the significance of mGlu2 receptors as targets for the regulation of behaviors dependent on hyperglutamatergic signaling. LY341495 is only one order of magnitude less potent as an antagonist at mGlu8 receptors (Kingston et al., 1998). Since BINA has not been evaluated at this subtype, the possible contribution of mGlu8 receptors, although unlikely, can not be ruled out.

Delineating the neuroanatomical site of action responsible for the behavioral effects of systemically administered drugs is a difficult task. Microinjection of the hallucinogenic 5-HT_{2A/2C} receptor agonist (\pm)DOI into the mPFC of rats has been shown to induce the head twitch response (Willins and Meltzer, 1997). Here we confirm this site using an additional design often employed to link the behavioral actions of drugs to a brain site of action, *in vivo* induction of immediate early gene expression. The induction of the immediate early gene *cfos* and the expression of its protein product Fos is a postsynaptic event linked to the activation of ionotropic glutamate receptors (Hughes and Dragunow, 1995; Platenik et al., 2000). (-)DOB induced Fos expression in mPFC,

MOL #35170

anterior cingulate cortex, frontoparietal cortex, and SSC in a pattern similar to that previously observed with other hallucinogens (Leslie et al., 1993; Abi-Saab et al., 1998; Scruggs et al., 2000; Gresch et al., 2002; Zhai et al., 2003). In the current experiments, we utilized a drug treatment regimen to regulate Fos expression that closely mimicked the one shown to be behaviorally efficacious. At a behaviorally active dose, BINA attenuated (-)DOB activation of Fos expression in the mPFC, but not in the SSC, mimicking the effect of the mGlu2/3 receptor agonist LY379268 (Zhai et al., 2003). While both of these regions have been shown to display 5-HT_{2A} receptor-mediated Fos expression, only expression in the mPFC is regulated by mGlu2 receptors, a difference linked to distinct mGlu2 receptor expression in the thalamic neurons projecting to these regions (Ohishi et al., 1993a,b). Therefore, the blockade of (-)DOB-induced Fos expression in the mPFC, but not SSC, by the selective activation of mGlu2 receptors further supports the role of glutamate released from thalamocortical afferents in the *in vivo* actions of hallucinogens. Additionally, these observations are consistent with the neuroanatomical specificity of the actions of mGlu2 receptors, illustrating that *in vivo* mGlu2 receptors are key regulators of glutamatergic neurotransmission in select regions of the cortex, notably the mPFC.

This study takes a comprehensive experimental approach to delineate the role of mGlu2 receptors in the regulation of glutamatergic neurotransmission in the mPFC and in a model of psychosis. Results with the selective mGlu2 receptor allosteric potentiator BINA demonstrate that this novel class of allosteric regulators of metabotropic receptors elicits robust *in vitro* and *in vivo* effects. BINA attenuated the 5-HT-mediated EPSCs in layer V pyramidal neurons, confirming a physiological antagonism between mGlu2

MOL #35170

receptors and 5-HT_{2A} receptors. Analysis of BINA regulation of (-)DOB-induced Fos expression and head twitch response clearly indicates that selective activation of mGlu2 receptors is capable of attenuating hallucinogenic drug action and illustrates their convergence on glutamatergic neurotransmission in the mPFC. This class of glutamatergic drugs, whose function is mechanistically distinct from the direct agonists, warrants further investigation for their therapeutic potential. Since they interact with an allosteric site to potentiate endogenous glutamate, allosteric potentiators are predicted to produce more subtle, ordered effects and hence be sheltered from potential pitfalls of the direct agonists, such as desensitization and tolerance development.

MOL #35170

Acknowledgements

We thank Ms Kathleen Patterson for her skillful technical assistance. This research was supported in part by NIH research grants MH34007 and DA05181.

MOL #35170

References

- Abi-Saab WM, Bubser M, Roth RH, Deutch AY (1998) 5-HT₂ receptor regulation of extracellular GABA levels in the prefrontal cortex. *Neuropsychopharmacology* 20: 92-96
- Aghajanian GK, Marek GJ (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. *Neuropharmacology* 36: 589-599
- Aghajanian GK, Marek GJ (1999) Serotonin, via 5HT_{2A} receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. *Brain Res* 825: 161-171
- Aghajanian GK, Marek G (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. *Brain Res Rev* 31: 302-312
- Cartmell J, Monn JA, Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. *J Pharmacol Exp Ther* 291: 161-70
- Chaudhuri A (1997) Neural activity mapping with inducible transcription factors. *Neuroreport* 8: 3-7
- Cleghorn JM, Garnett ES, Nahmias C, Firnau G, Brown GM, Kaplan R, Szechtman H, Szechtman B (1989) Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. *Psychiatry Res* 28: 119-33
- Ebmeier KP, Lawrie SM, Blackwood DH, Johnstone EC, Goodwin GM (1995) Hypofrontality revisited: A high resolution single photon emission computed tomography study in schizophrenia. *J Neurol Neurosurg Psychiatry* 58: 452-456

MOL #35170

Franklin KBJ, Paxinos G (2003) *The Mouse Brain in Stereotaxic Coordinates*, Compact 2nd edn. Academic Press Inc. San Diego, CA.

Galici R, Echemendia NG, Rodriguez AL, Conn PJ (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. *J Pharmacol Exp Ther* 315: 1181-7

Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, Conn PJ (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. *J Pharmacol Exp Ther* 318: 173-85

Gewirtz JC, Marek GJ (2000) Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. *Neuropsychopharmacology* 23: 569-576

Greco B, Invernizzi RW, Carli M (2005) Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268. *Psychopharmacology (Berl)* 179: 68-76

Gresch PJ, Strickland LV, E. Sanders-Bush (2002) Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors. *Neuroscience* 114: 707-713

Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M (1992) Mescaline-induced psychopathological, neuropsychological,

MOL #35170

- and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. *Biol Psychiatry* 32: 976-91
- Hughes P, Dragunow M (1995) Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. *Pharmacol Rev* 47: 133-78
- Johnson MP, Baez M, Jagdmann GE, Jr., Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. *J Med Chem* 46: 3189-92
- Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). *Psychopharmacology* 179: 271-83
- Kaplan RD, Szechtman H, Franco S, Szechtman B, Nahmias C, Garnett ES, List S, Cleghorn JM (1993) Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by positron emission tomography (PET). *Schizophr Res* 11: 47-54
- Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, Schoepp DD (1998) LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. *Neuropharmacology* 1:1-12.

MOL #35170

Klodzinska A, Bijak M, Tokarski K, Pilc A (2002) Group II mGlu receptor agonists

inhibit behavioural and electrophysiological effects of DOI in mice. *Pharmacol Biochem Behav* 73: 327-332

Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L,

Hunsberger T, Belger A, Levine L, Breier A (2004) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.

Psychopharmacology 179: 303-09

Leslie RA, Moorman JM, Coulson A, Grahame-Smith DG (1993) Serotonin_{2/1C} receptor

activation causes a localized expression of the immediate-early gene c-fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibres.

Neuroscience 53: 457-463

Marek GJ, Wright RA, Gewirtz JC, Schoepp DD (2001) A major role for thalamocortical

afferents in serotonergic hallucinogen receptor function in the rat neocortex.

Neuroscience 105: 379-392

Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK (2000) Physiological

antagonism between 5-hydroxytryptamine 2A and group II metabotropic glutamate receptors in prefrontal cortex. *J Pharmacol Exp Ther* 292: 76-87

Moghaddam B, Adams B (1998) Reversal of phencyclidine effects by a group II

metabotropic glutamate receptor agonist in rats. *Science* 281: 1349-1352

MOL #35170

- Ohishi H, Shigemoto R, Nakanishi S, Mizuno N (1993a) Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. *Neuroscience* 53: 1009-18
- Ohishi H, Shigemoto R, Nakanishi S, Mizuno N (1993b) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. *J Comp Neurol* 335: 252-66
- Platenik J, Kuramoto N, Yoneda Y (2000) Molecular mechanisms associated with long-term consolidation of the NMDA signals. *Life Sci* 67: 335-64
- Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, Vernier JM, Bristow LJ, Varney MA, Daggett LP (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. *Mol Pharmacol* 64: 798-810
- Schoepp, DD (2006) New directions in the treatment of schizophrenia: Modulators of mGlu2 and/or mGlu3 receptors. *Neuropsychopharmacology* 31: S25
- Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995) (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT_{2A/2C} antagonists, D1 antagonists and 5-HT_{1A} agonists. *J Pharmacol Exp Ther* 273: 101-12
- Scruggs JL, Patel S, Bubser M, Deutch AY (2000) DOI-induced activation of the cortex: dependence on 5HT_{2A} heteroreceptors on thalamocortical glutamatergic neurons. *J Neurosci* 20: 8846-8852

MOL #35170

- Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. *Brain Res Bull* 56: 495-507
- Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). *Eur Neuropsychopharmacol* 7: 9-24
- Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. *Neuropsychopharmacology* 16: 357-72
- Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. *Neuroreport* 9: 3897-3902
- Willins DL, Meltzer HY (1997) Direct injection of 5-HT_{2A} receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. *J Pharmacol Exp Ther* 282: 699-706
- Winter JC, Eckler JR, Rabin RA (2004) Serotonergic/glutamatergic interactions: the effects of mGluR2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. *Psychopharmacology* 172: 233-240
- Zhai Y, Carolyn GA, Zhai J, Nisenbaum ES, Johnson MP, Nisenbaum LK (2003) Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. *Neuropsychopharmacology* 28: 45-52

MOL #35170

Footnotes

This research was supported in part by grants from NIMH (ESB, PJC), NIDA (ESB), and NINDS (PJC).

MOL #35170

Figure Legends

Figure 1. Synergistic action of DCG-IV and BINA on baseline spontaneous EPSCs. Cumulative probability plots for the cell illustrated in Panel A shows the effect of the mGlu2/3 receptor agonist DCG-IV (1 μ M) on the frequency (Panel B) and amplitude (Panel C) of baseline EPSCs measured in layer V pyramidal neurons of the rat mPFC. Averaged (n=5) frequency and amplitude of baseline EPSCs are presented in Panel D. Data normalized to control condition. Significant difference from control indicated by asterisk (* p<0.05, student's t-test). Cumulative probability plots for the cell illustrated in Panel E shows the effect of DCG-IV (200nM) on the frequency (Panel F) and amplitude (Panel G) of baseline EPSCs. Averaged (n=6) frequency and amplitude are presented in Panel H. Cumulative probability plots for the cell illustrated in Panel I shows the effect of the mGlu2 receptor allosteric potentiator BINA (3 μ M) alone (n=6) and in the presence (n=6) of DCG-IV (200nM) on the frequency (Panel J) and amplitude (Panel K) of baseline EPSCs with Panel L showing averaged frequency and amplitude. Asterisks indicate significant differences from control (* p<0.05, ** p<0.01; student's t-test).

Figure 2. Attenuation of 5-HT-induced EPSCs by BINA and DCG-IV, and the reversal of BINA by LY341495. The effect of BINA (3 μ M) on 5-HT (10 μ M) induced EPSCs is shown in Panels A-C. Cumulative probability plots for the traces of the cell illustrated in Panel A show a reduction in frequency (Panel B) and amplitude (Panel C) of 5-HT-induced EPSCs. The effect of DCG-IV (100nM) on 5-HT-induced EPSCs is illustrated

MOL #35170

in Panels D-F. Cumulative probability plots for the traces of the cell illustrated in Panel D show a reduction in frequency (Panel E) and amplitude (Panel F) of 5-HT-induced EPSCs. LY341495 (100nM) prevents the effect of BINA on 5-HT-induced EPSCs (panels G-I). Cumulative probability plots for the traces of the cell illustrated in Panel G show a minimal change in frequency (Panel H) and amplitude (Panel I) of 5-HT-induced EPSCs. Average frequency (Panel J) and amplitude (Panel K) of 5-HT (10 μ M) induced EPSCs after 9 minutes of stimulation, in the presence of BINA (3 μ M), DCG-IV (100nM), BINA (3 μ M) and LY341495 (100nM) or control, were normalized to maximum 5-HT stimulation observed at 2 minutes (n=5-6). Asterisks indicate significant difference from control (* p<0.05, ** p<0.01; student's t-test).

Figure 3. LY341495 reverses BINA-mediated blockade of (-)DOB-induced head twitch response. All mice were administered 0.3 mg/kg (-)DOB (s.c.). Animals were divided into 4 pretreatment groups (n=6), given saline or LY341495 (3.0 mg/kg, i.p.) 10 minutes prior to vehicle or BINA (65 mg/kg, i.p.) 30 minutes prior to (-)DOB. (*)Saline/BINA versus Saline/Vehicle (p<0.001, Newman-Keuls). (†) Saline/BINA versus LY341495/BINA (p<0.001, Newman-Keuls). LY341495/Vehicle pretreatment is not different than Saline/Vehicle or LY341495/BINA.

Figure 4. Schematic illustrations of the areas in which Fos expression was analyzed. Fos-LI positive cells were counted in highlighted regions of sections (based on Franklin and Paxinos, 2003) containing medial prefrontal cortex (+1.70 mm relative to bregma) and somatosensory cortex (+0.74 mm relative to bregma).


MOL #35170












Table 1. Modulation of (-)DOB-induced Fos-like immunoreactivity in medial prefrontal cortex (mPFC) and somatosensory cortex (SSC).


Animals (n=6-8 per group) were given LY341495 (3.0 mg/kg, i.p.) or saline 10 minutes prior to BINA (65 mg/kg, i.p.) or vehicle 40 minutes prior to (-)DOB (1.0 mg/kg, s.c.) or saline. Shown is the number of Fos-LI positive cells in the region of the mPFC or SSC analyzed. BINA attenuated the (-)DOB-induced Fos expression in the mPFC, but not the SSC, an effect reversed by the mGlu2/3 receptor antagonist LY341495. BINA did not significantly altered Fos expression alone. LY341495 significantly increased saline-induced, but not (-)DOB-induced Fos expression.

Drug treatments (mg/kg)	Number of Fos-LI positive cells	
	mPFC	SSC
Saline – Vehicle – Saline	29.1 ±4.2	0.13 ±0.085
LY341495 – Vehicle – Saline	50.3 ±7.2 *,†	0.57 ±0.25
Saline – BINA – Saline	30.4 ±4.0	1.2 ±0.38
Saline – Vehicle – DOB	51.4 ±4.1 *,†	37.0 ±5.4 *
Saline – BINA – DOB	30.4 ±4.0	46.3 ±10.5 *
LY341495 – Vehicle – DOB	65.0 ±7.4 *,†	52.4 ±12.2 *
LY341495 – BINA – DOB	58.4 ±6.3 *,†	67.8 ±14.9 *

(*) indicates significant difference from Saline-Vehicle-Saline treatment
 (†) indicates significant difference from Saline-BINA-DOB treatment







DOB (0.3 mg/kg)

+

+

+

+

BINA (65 mg/kg)

-

+

-

+

LY341495 (3.0 mg/kg)


-

-

+

+

Bregma +1.70 mm



Bregma +0.74 mm

